About Olfactory receptor 4C13
Olfactory receptor 4C13 (OR4C13) is a protein
from Homo sapiens identified by UniProt accession
Q8NGP0, 309 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Olfactory receptor 4C13 |
|---|
| UniProt accession | Q8NGP0 |
|---|
| Gene | OR4C13 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 309 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (62)
Diseases linked to this target (Open Targets).
- systolic blood pressure · score 0.37
- creatinine measurement · score 0.36
- IGF-1 measurement · score 0.35
- neurodegenerative disease · score 0.30
- serum gamma-glutamyl transferase measurement · score 0.27
- pulse pressure measurement · score 0.25
- aspartate aminotransferase measurement · score 0.25
- high density lipoprotein cholesterol measurement · score 0.24
- serum metabolite measurement · score 0.23
- apolipoprotein A 1 measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NGP0-F1 | alphafold | PREDICTED | 88.25 | — |
Amino-acid sequence (309 residues)
MANRNNVTEF ILLGLTENPK MQKIIFVVFS VIYINAMIGN VLIVVTITAS PSLRSPMYFF LAYLSFIDAC YSSVNTPKLI TDSLYENKTI LFNGCMTQVF GEHFFRGVEV ILLTVMAYDH YVAICKPLHY TTVMKQHVCS LLVGVSWVGG FLHATIQILF ICQLPFCGPN VIDHFMCDLY TLINLACTNT HTLGLFIAAN SGFICLLNCL LLLVSCVVIL YSLKTHSLEA RHEALSTCVS HITVVILSFI PCIFVYMRPP ATLPIDKAVA VFYTMITSML NPLIYTLRNA QMKNAIRKLC SRKAISSVK
Explore Olfactory receptor 4C13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets